In this review, we discuss two relatively newer classes of medication for diabetes mellitus that have been increasingly recognized in recent years as agents that could assist in the prevention of CVD, namely SGLT‐2 inhibitors and glucagon‐like peptide 1 (GLP‐1) agonists. The gene discussed is GCG; the disease is diabetes mellitus.